Results 11 to 20 of about 381 (103)

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo [PDF]

Medical Mycology, 2023
Abstract Mycetoma is a neglected tropical disease commonly caused by the fungus Madurella mycetomatis. Standard treatment consists of extensive treatment with itraconazole in combination with surgical excision of the infected tissue, but has a low success rate. To improve treatment outcomes, novel treatment strategies are needed.
Nikolaos Strepis, Bertrand Nyuykonge, Wendy van de Sande   +2 more
exaly   +7 more sources

Candida auris: a review of global epidemiology, multidrug resistance, and infection control in healthcare-associated outbreaks [PDF]

Frontiers in Cellular and Infection Microbiology
Candida auris, designated a critical-priority fungal pathogen by the World Health Organization, poses a growing threat to healthcare systems worldwide. Analysis of 80 peer-reviewed studies reveals five principal findings: (1) C.
Xuewei Du, Li Li
doaj   +2 more sources

New Perspectives on Antimicrobial Agents: Fosmanogepix [PDF]

Antimicrobial Agents and Chemotherapy
Invasive fungal infections (IFIs) are associated with high mortality rates and pose important therapeutic challenges because of the limited number of antifungal drug classes, their toxicity, and the emergence of resistance.
Frederic Lamoth
doaj   +2 more sources

Invasive Mould Infections Following Combat-Related Injuries-A Retrospective Cohort Study. [PDF]

Mycoses
ABSTRACT Background Available data on combat wound‐related invasive mould infections (IMIs) are limited. Objectives We aimed to describe the characteristics and outcomes of IMIs in casualties of a recent conflict. Patients/Methods A retrospective study including hospitalised patients with combat‐related injuries, fulfilling criteria for wound‐related ...
Hoffman T, Haviv Y, Cohen A, Nesher L, Schlaeffer-Yosef T, Azulay H, Brosh-Nissimov T, Amit S, Gazit Z, Tribble DR, Ben-Ami R, Yahav D.   +11 more
europepmc   +2 more sources

Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update). [PDF]

Mycoses
ABSTRACT Background Central nervous system (CNS) aspergillosis is a life‐threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics ...
Mansour MA, Wahid M, El Molla MAS, Helmy MH, Adel TM, Mostafa HN.   +5 more
europepmc   +2 more sources

Antifungal Susceptibility of Saccharomyces cerevisiae Isolated from Clinical Specimens [PDF]

Pathogens
(1) Background: Despite being considered a non-pathogenic yeast, recently, a growing occurrence of Saccharomyces cerevisiae infections has been noted. There is little knowledge about the drug susceptibility of this species.
Aleksandra Górzyńska, Kamila Kondracka, Agnieszka Korzeniowska-Kowal, Urszula Nawrot   +3 more
doaj   +2 more sources

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fungal infections.
Kapoor, Mili, Moloney, Molly, Soltow, Quinlyn A., Pillar, Chris M., Shaw, Karen Joy   +4 more
openaire   +5 more sources

<i>Candidozyma auris</i> susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents. [PDF]

JAC Antimicrob Resist
Abstract Background Candidozyma auris (C. auris) is a resistant fungal pathogen with high mortality. Objectives To evaluate the in vitro activity of 11 antifungal agents against C. auris from multiple hospitals.
Klamer KS, Bhargava A, Johnson L, Sharma M, Saravolatz LD.   +4 more
europepmc   +2 more sources

Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis

mBio, 2022
Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 inhibitor APX2039, in a mouse model of CM.
Charles D. Giamberardino, Wiley A. Schell, Jennifer L. Tenor, Dena L. Toffaletti, Julia R. Palmucci, Choiselle Marius, Jane-Valeriane K. Boua, Quinlyn Soltow, Robert Mansbach, M. Arthur Moseley, J. Will Thompson, Laura G. Dubois, William Hope, John R. Perfect, Karen Joy Shaw   +14 more
doaj   +1 more source

In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak [PDF]

Antimicrobial Agents and Chemotherapy, 2020
An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY C. auris isolates are resistant to fluconazole, with variable resistance to other currently used ...
YanChun Zhu, Shannon Kilburn, Mili Kapoor, Sudha Chaturvedi, Karen Joy Shaw, Vishnu Chaturvedi   +5 more
openaire   +3 more sources